Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Novo Nordisk has recently completed a clinical study titled ...

The 'Ladies First' rapper has partnered with Novo Nordisk to create more awareness around obesity and cardiovascular disease Karwai Tang/WireImage Queen Latifah shared how losing her cousin to ...

Eli Lilly (LLY -0.40%) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NVO 1.20%) being its biggest challenger.

On an absolute basis, the inflammation-lowering efficacy of the Tourmaline drug, called pacibekitug, was comparable to the results shown previously by Novo Nordisk for its similar heart-disease ...

Written by Zacks Equity Research for Zacks -> Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership and board of directors.

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

The runaway success of GLP-1 drugs made Novo Nordisk, a Danish drugmaker, the top company in Europe by market cap. These medications, injected into the body, mimic a hormone that regulates blood ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.

We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 for obesity.

References 1. Novo Nordisk expands patient access to authentic, FDA-approved Wegovy via collaborations with multiple telehealth organizations. News release. Novo Nordisk. April 29, 2025.

The trial, funded by drugmaker Novo Nordisk, included 800 patients with MASH from 37 countries. Patients either got a weekly 2.4 milligram dose of semaglutide, the active ingredient in Ozempic and ...